TESTOSTERONE LEVELS IN MEN WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS AFTER TRANSPLANTATION OF AUTOLOGOUS MESENCHYMAL STEM CELLS

Abstract

OBJECTIVES
To study the effect of autologous mesenchymal stem cells transplantation (AMSCT) on testosterone levels in men with Diabetes Mellitus Type 1 (T1DM) and Type 2 (T2DM).

METHODOLOGY
5 male DMT1and DMT2 patients (39-50 years old) who received AMSCT intravenously were compared to 5 male DMT1and DMT2 patients (32-56 years old) as the control group. Mesenchymal stem cells were obtained from the iliac crest of DMT1 and DMT2 patients, the cells were cultured for 3-4 weeks and infused (95-97 × 106). Glycated hemoglobin (HbA1C,%) and testosterone (ng/ml) levels in both groups were analyzed before and 3 months later after the AMSCT.

RESULTS
The baseline mean testosterone and HbA1C levels in men with DMT1 and DMT2 with AMSCT were -5.31 + 2.12 ng/ ml and 9.45 + 1.24 % respectively. Three months after the AMSCT, the mean testosterone and HBA1c became -6.33 + 2.12 ng/ml (p=0.82) and 8.53 + 1.08% (p=0.25). The baseline mean testosterone and HbA1C levels in DMT1 and DMT2 men in the control group were 5.27 + 1.8 ng/ml and 8.84 + 2.2% respectively. Three months after, the testosterone was -3.69 + 1.18 ng/ml (p=0,179) and the HBA1c was 8.64 + 1.41% (p=0.19). After 3 months, the average testosterone level in men with DMT1 and DMT2 who underwent AMSCT significantly increased compared to the mean testosterone level in men of the control group: 6.33 + 2.12 ng/ml versus 3.69 + 1.18 ng/ml (p=0.015).

CONCLUSION
An increase in testosterone levels in men with DMT1 and DMT2 after 3 months of the AMSCT compared with the control group of men with DMT1 and DMT2 can serve as a confirmation of the effectiveness of AMSCT for the prevention of diabetic erectile dysfunction and hypogonadism in men with diabetes mellitus.